AI workflow enhances precision of progression-free survival estimates in metastatic breast cancer, enabling more effective and personalized treatmentsCAMBRIDGE, Mass.--(BUSINESS WIRE)--nference,...
TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to...
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with...
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced...
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued...
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR...
SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a...
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for...
Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies...
Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus'' or the "Company"), a leader...
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - In a significant stride towards transforming mental health care, Numinus Wellness...
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology...
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...